Marlene Chakhtoura1, Mona Nasrallah1, Hassan Chami2,3. 1. Division of Endocrinology at the American University of Beirut, Beirut Lebanon. 2. Division of Pulmonary, Sleep and Critical Care Medicine at the American University of Beirut, Beirut Lebanon. 3. Pulmonary Center at Boston University School of Medicine, Boston, MA.
Abstract
INTRODUCTION: Obstructive sleep apnea (OSA) is a common sleep-related respiratory disorder. It is associated with many endocrinopathies including hypogonadotropic hypogonadism, hypercortisolism, and glucose intolerance that may lead to bone loss with secondary osteoporosis. METHODS: We report the case of a 41-year-old man who presented with bilateral 9th rib fractures and was found to have obstructive sleep apnea and osteoporosis. We also present a literature review on this topic. RESULTS: OSA can lead to bone loss through various mechanisms. Some are shared with obesity, including hypogonadism, altered adrenergic tone, inflammation, oxidative stress, vitamin D deficiency and diabetes mellitus; others are specific to OSA, such as hypoxia and altered glucocorticoids regulation. CONCLUSION: There are no guidelines on screening for osteoporosis in OSA. Further research is needed to assess the incidence of bone loss and fractures in OSA.
INTRODUCTION:Obstructive sleep apnea (OSA) is a common sleep-related respiratory disorder. It is associated with many endocrinopathies including hypogonadotropic hypogonadism, hypercortisolism, and glucose intolerance that may lead to bone loss with secondary osteoporosis. METHODS: We report the case of a 41-year-old man who presented with bilateral 9th rib fractures and was found to have obstructive sleep apnea and osteoporosis. We also present a literature review on this topic. RESULTS: OSA can lead to bone loss through various mechanisms. Some are shared with obesity, including hypogonadism, altered adrenergic tone, inflammation, oxidative stress, vitamin Ddeficiency and diabetes mellitus; others are specific to OSA, such as hypoxia and altered glucocorticoids regulation. CONCLUSION: There are no guidelines on screening for osteoporosis in OSA. Further research is needed to assess the incidence of bone loss and fractures in OSA.
Authors: Patricia Lloberes; Joaquín Durán-Cantolla; Miguel Ángel Martínez-García; José María Marín; Antoni Ferrer; Jaime Corral; Juan Fernando Masa; Olga Parra; Mari Luz Alonso-Álvarez; Joaquín Terán-Santos Journal: Arch Bronconeumol Date: 2011-03 Impact factor: 4.872
Authors: O Resta; M P Foschino-Barbaro; G Legari; S Talamo; P Bonfitto; A Palumbo; A Minenna; R Giorgino; G De Pergola Journal: Int J Obes Relat Metab Disord Date: 2001-05
Authors: J-M Kaufman; J-Y Reginster; S Boonen; M L Brandi; C Cooper; W Dere; J-P Devogelaer; A Diez-Perez; J A Kanis; E McCloskey; B Mitlak; E Orwoll; J D Ringe; G Weryha; R Rizzoli Journal: Bone Date: 2012-11-28 Impact factor: 4.398
Authors: H Eimar; H Saltaji; S Ghorashi; D Isfeld; J E MacLean; D Gozal; D Graf; C Flores-Mir Journal: Osteoporos Int Date: 2017-01-18 Impact factor: 4.507